Novartis to invest $500m in Russia
Novartis, the Swiss pharmaceuticals group, plans to invest $500m in Russia in the coming five years in a move to bolster its position in the market and bypass tougher regulations on imported medicines.
Swiss pharmaceutical group Novartis said Tuesday that it would invest 1.0 billion dollars in research and development in China to latch on to growing demand for health care.